Companies
/
Xiaohongshu (Red Note)
Media & Entertainment
Xiaohongshu is a lifestyle platform where millions share content on beauty, fashion, travel, and more — blending community insights with commerce to inspire discovery and connection.
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
The company's approach combines advanced AI models for protein structure prediction and, notably, protein design, meaning not only predicting how existing proteins fold but designing entirely novel proteins with specific desired properties and functions, a capability that, if successfully commercialized at scale, could significantly accelerate the traditionally slow, expensive, and high-failure-rate process of drug discovery by letting researchers computationally design and screen promising drug candidate molecules and biological therapeutics with much greater precision and speed than traditional laboratory-based experimental approaches alone typically allow. Xaira has assembled a research team spanning both AI and computational biology expertise and traditional pharmaceutical drug development experience, reflecting the company's ambition to genuinely integrate AI-driven computational drug design with the practical clinical development, regulatory, and commercialization expertise needed to actually bring new AI-designed therapeutics through clinical trials and regulatory approval to patients, rather than only demonstrating computational drug design capability without the broader capabilities needed to translate that computational work into approved medicines. The company has pursued drug discovery programs across multiple disease areas, leveraging its AI-driven protein design platform as a foundational technology applicable across many different specific disease targets and therapeutic areas rather than being narrowly focused on only one specific disease area. Xaira's extraordinarily large initial funding, from investors including ARCH Venture Partners, Sequoia Capital, and Foresite Capital, reflects broader intense investor interest in AI-driven drug discovery as one of the most promising near-term commercial applications of recent AI breakthroughs in protein structure prediction and biological modeling.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
